Pregabalin Capsule
Product Images NDC 71205-621

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-621). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-621-60 (Pregabalin 75mg 90s)

Pregabalin 75 mg capsules packaging label by Proficient Rx LP. The label indicates 60 capsules per container, with each white/orange hard gelatin capsule imprinted with 'A009' on the cap and 'PREG 75' on the body. Manufactured by Alkem Laboratories Ltd., Mumbai, India. The label includes NDC 71205-621-60, C-V controlled substance classification, storage instructions, and barcodes.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A text panel showing the formula for calculating creatinine clearance (CLCr), indicating the variables: age in years, weight in kg, serum creatinine in mg/dL, and a multiplication factor of 0.85 specifically for female patients.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph showing responder rates (%) from two clinical studies, Study E1 and Study E3, comparing various dosages of Pregabalin and placebo. Study E1 includes placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses, with rates ranging from 14% to 51%. Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID doses, with responder rates from 9% to 49%. Statistically significant differences versus placebo are indicated for certain dosages.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for Pregabalin. It compares four study groups: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. The graph includes significant p-values indicating statistical significance of the reductions at various doses up to 600 mg/day, with placebo at dose zero.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 75 mg three times a day, Pregabalin 150 mg three times a day, Pregabalin 250 mg three times a day, and placebo, with higher doses generally showing greater improvement.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line chart comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12, depicting two groups: Pregabalin and Placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. The Pregabalin group is represented by a solid line, and the Placebo group by a dashed line, with the Pregabalin line consistently above the Placebo line across the range.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved from baseline to Week 16 according to the Beck Depression Inventory (BDI) for Pregabalin and Placebo. The y-axis represents the percent of subjects improved, ranging from 0 to 100, while the x-axis shows the percent improvement from baseline to Week 16 BDI, spanning values approximately from 0 to 100. Two curves are shown, one solid line for Pregabalin and one dashed line for Placebo, illustrating higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two lines represent Pregabalin 100 mg three times a day and placebo groups, showing comparative patient improvement levels across different percentages of pain improvement.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph displaying percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken twice a day, plus a placebo. The y-axis shows the percent of patients improved from 0 to 100, and the x-axis shows percent improvement in pain from baseline from 0 to 300.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph showing the percent of patients improved relative to the percent improvement in pain from baseline. The graph compares three groups: patients treated with Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating the distribution of pain improvement percentages across the groups.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph depicting the percent improvement in pain from baseline versus the percent of patients improved. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing the trend of patient improvement across increasing percentages of pain reduction.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares Pregabalin at 600 mg, 450 mg, and 300 mg daily doses against a placebo, showing patient improvement trends across different pain relief levels.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over a 180-day period between Pregabalin and placebo groups. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis shows time in days. Pregabalin group shows a higher survival rate compared to placebo throughout the duration.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin depicting its molecular arrangement with amino and carboxyl functional groups attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.